Britain’s medicines regulator authorized Eli Lilly and Company’s (NYSE: LLY) oral GLP-1 drug orforglipron on August 10, making the UK the first European country to approve the pill.
The UK’s Medicines and Healthcare Products Regulatory Agency cleared orforglipron, marketed under the brand name Foundayo, for weight loss and maintenance in obese adults and select overweight individuals with weight-related health conditions.
The approval also covers blood sugar control in adults living with type 2 diabetes, broadening the drug’s commercial scope beyond obesity treatment alone.
Shares of LLY rose more than 2% following the announcement, a measured but meaningful signal for a company whose weight-loss franchise has become the single most important driver of its market value.
Foundayo distinguishes itself from the broader GLP-1 category by being a small, non-peptide receptor agonist taken as a single daily tablet, with no food or water restrictions required around dosing.
That convenience factor sets it apart from competing oral peptide alternatives, which often require strict fasting windows, and from injectable drugs like Lilly’s own Zepbound and Novo Nordisk A/S’s (NYSE: NVO) Ozempic.
Clinical data supporting the approval is robust, with the ATTAIN-1 trial tracking 3,127 individuals with obesity over 72 weeks, showing participants on the 36 mg dose lost an average of 11.2% of their body weight versus 2.1% on placebo.
More than half of participants on the 36 mg dose lost at least 10% of their body weight, a threshold widely considered clinically meaningful in obesity treatment research.
Despite the regulatory clearance, Foundayo is not currently available through the National Health Service, as the National Institute for Health and Care Excellence is completing its own cost-effectiveness evaluation, with a decision expected on November 18.
Until NICE reaches its conclusion, UK patients seeking Foundayo will need to pay out of pocket or access it through private prescribers, a situation already familiar to users of competing products in the category.
The UK clearance places Lilly in direct competition with Novo Nordisk, whose own oral weight-loss tablet, a pill variant of Wegovy, was approved in the UK in June and has since added higher-dose 9 mg and 25 mg options through private prescribers.
Competition between the two companies in this market is expected to hinge on relative efficacy, tolerability, pricing, and manufacturing supply capacity, all of which will likely shape prescribing patterns once NHS reimbursement decisions are made.
Institutional sentiment toward Lilly remains broadly positive, though hedge fund ownership dipped marginally from 137 funds in the fourth quarter of 2025 to 132 funds in the first quarter of 2026, according to 13F filing data.
Lilly currently trades at a forward price-to-earnings ratio of 25.99x, a premium that reflects investor confidence in its dual-growth narrative anchored by Mounjaro, Zepbound, and its expanding oral GLP-1 pipeline.
The November 18 NICE ruling represents the next critical catalyst for the stock, with cash-pay pricing dynamics and production scale relative to Novo Nordisk’s oral Wegovy likely to guide near-term trading direction.
